Mentor Capital Inc. in San Diego, California plans to extend its funding beyond cancer immunotherapy — its current specialty — to other leading cancer solutions. Its objective is to provide investments that fill the gap for therapies between initial lab development and their acquisition by major pharmaceutical companies. This middle stage is often called “The Valley of Death” by biotech and pharmaceutical companies trying to commercialize their findings.
Company CEO Chet Billingsley says a number of research foundations, “have done an outstanding job unearthing promising cancer solutions.” Billingsley adds, “Through their sponsorship we know that genetically tailored medicines and immunotherapies can focus the body’s own defenses to attack cancer cells.” He notes, however, that funding often dries up for development companies that try to take laboratory solutions through the FDA registration process, and Mentor Capital is stepping in to fill that void.
Mentor Capital started the Mentor Capital Cancer Immunotherapy Index that tracks the financial performance of companies it funds that are involved in immunotherapy research. Mentor is also exploring other cancer funding options with separate investment companies, as well as acquisitions of and investments in other cancer research enterprises.
Photo: Daniel Borman/Flickr
* * *
RSS - Posts
You must be logged in to post a comment.